Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon

Xia Wang, Debi P. Sarkar, Prashant Mani, Clifford J. Steer, Yong Chen, Chandan Guha, Voshavar Chandrasekhar, Arabinda Chaudhuri, Namita Roy-Chowdhury, Betsy T. Kren, Jayanta Roy-Chowdhury

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Asialoglycoprotein receptor (ASGPR)-mediated endocytosis has been used to target genes to hepatocytes in vivo. However, the level and duration of transgene expression have been low because of lysosomal translocation and degradation of the DNA and lack of its integration into the host genome. In this study we packaged the DNA of interest in proteoliposomes containing the fusogenic galactose-terminated F-glycoprotein of the Sendai virus (FPL) for targeted delivery to hepatocytes. After the FPL binds to ASGPR on the hepatocyte surface, fusogenic activity of the F-protein delivers the DNA into the cytosol, bypassing the endosomal pathway. For transgene integration we designed plasmids containing one transcription unit expressing the Sleeping Beauty transposase (SB) and another expressing human uridinediphosphoglucuronate glucuronosyltransferase-1A1 (pSB-hUGT1A1). The latter was flanked by inverted/direct repeats that are substrates of SB. In cell culture, FPL-mediated delivery of the E. coli β-galactosidase gene (LacZ) resulted in transduction of ASGPR-positive cells (rat hepatocytes or Hepa1 cell line), but not of ASGPR-negative 293 cells. Intravenous injection of the FPL-entrapped pSB-hUGT1A1 (4-8 μg/day, 1-4 doses) into UGT1A1-deficient hyperbilirubinemic Gunn rats (model of Crigler-Najjar syndrome type 1) resulted in hUGT1A1 expression in 5%-10% of hepatocytes, but not in other cell types. Serum bilirubin levels declined by 30% ± 4% in 2 weeks and remained at that level throughout the 7-month study duration. With histidine containing FPL, serum bilirubin was reduced by 40% ± 5%, and bilirubin glucuronides were excreted into bile. No antibodies were detectable in the recipient rats against the F-protein or human UGT1A1. Conclusion: FPL is an efficient hepatocyte-targeted gene delivery platform in vivo that warrants further exploration toward clinical application.

Original languageEnglish (US)
Pages (from-to)815-824
Number of pages10
JournalHepatology
Volume50
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Gunn Rats
Beauty
Jaundice
Asialoglycoprotein Receptor
Hepatocytes
Liver
Transposases
Transgenes
Bilirubin
DNA
Crigler-Najjar Syndrome
Galactosidases
Sendai virus
Glucuronosyltransferase
Lac Operon
Nucleic Acid Repetitive Sequences
Endocytosis
Serum
Galactose
Histidine

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon. / Wang, Xia; Sarkar, Debi P.; Mani, Prashant; Steer, Clifford J.; Chen, Yong; Guha, Chandan; Chandrasekhar, Voshavar; Chaudhuri, Arabinda; Roy-Chowdhury, Namita; Kren, Betsy T.; Roy-Chowdhury, Jayanta.

In: Hepatology, Vol. 50, No. 3, 2009, p. 815-824.

Research output: Contribution to journalArticle

Wang, X, Sarkar, DP, Mani, P, Steer, CJ, Chen, Y, Guha, C, Chandrasekhar, V, Chaudhuri, A, Roy-Chowdhury, N, Kren, BT & Roy-Chowdhury, J 2009, 'Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon', Hepatology, vol. 50, no. 3, pp. 815-824. https://doi.org/10.1002/hep.23060
Wang, Xia ; Sarkar, Debi P. ; Mani, Prashant ; Steer, Clifford J. ; Chen, Yong ; Guha, Chandan ; Chandrasekhar, Voshavar ; Chaudhuri, Arabinda ; Roy-Chowdhury, Namita ; Kren, Betsy T. ; Roy-Chowdhury, Jayanta. / Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon. In: Hepatology. 2009 ; Vol. 50, No. 3. pp. 815-824.
@article{da5e60e7d6c24e66bf7bdec7dffd46b4,
title = "Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon",
abstract = "Asialoglycoprotein receptor (ASGPR)-mediated endocytosis has been used to target genes to hepatocytes in vivo. However, the level and duration of transgene expression have been low because of lysosomal translocation and degradation of the DNA and lack of its integration into the host genome. In this study we packaged the DNA of interest in proteoliposomes containing the fusogenic galactose-terminated F-glycoprotein of the Sendai virus (FPL) for targeted delivery to hepatocytes. After the FPL binds to ASGPR on the hepatocyte surface, fusogenic activity of the F-protein delivers the DNA into the cytosol, bypassing the endosomal pathway. For transgene integration we designed plasmids containing one transcription unit expressing the Sleeping Beauty transposase (SB) and another expressing human uridinediphosphoglucuronate glucuronosyltransferase-1A1 (pSB-hUGT1A1). The latter was flanked by inverted/direct repeats that are substrates of SB. In cell culture, FPL-mediated delivery of the E. coli β-galactosidase gene (LacZ) resulted in transduction of ASGPR-positive cells (rat hepatocytes or Hepa1 cell line), but not of ASGPR-negative 293 cells. Intravenous injection of the FPL-entrapped pSB-hUGT1A1 (4-8 μg/day, 1-4 doses) into UGT1A1-deficient hyperbilirubinemic Gunn rats (model of Crigler-Najjar syndrome type 1) resulted in hUGT1A1 expression in 5{\%}-10{\%} of hepatocytes, but not in other cell types. Serum bilirubin levels declined by 30{\%} ± 4{\%} in 2 weeks and remained at that level throughout the 7-month study duration. With histidine containing FPL, serum bilirubin was reduced by 40{\%} ± 5{\%}, and bilirubin glucuronides were excreted into bile. No antibodies were detectable in the recipient rats against the F-protein or human UGT1A1. Conclusion: FPL is an efficient hepatocyte-targeted gene delivery platform in vivo that warrants further exploration toward clinical application.",
author = "Xia Wang and Sarkar, {Debi P.} and Prashant Mani and Steer, {Clifford J.} and Yong Chen and Chandan Guha and Voshavar Chandrasekhar and Arabinda Chaudhuri and Namita Roy-Chowdhury and Kren, {Betsy T.} and Jayanta Roy-Chowdhury",
year = "2009",
doi = "10.1002/hep.23060",
language = "English (US)",
volume = "50",
pages = "815--824",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Long-term reduction of jaundice in Gunn rats by nonviral liver-targeted delivery of Sleeping Beauty transposon

AU - Wang, Xia

AU - Sarkar, Debi P.

AU - Mani, Prashant

AU - Steer, Clifford J.

AU - Chen, Yong

AU - Guha, Chandan

AU - Chandrasekhar, Voshavar

AU - Chaudhuri, Arabinda

AU - Roy-Chowdhury, Namita

AU - Kren, Betsy T.

AU - Roy-Chowdhury, Jayanta

PY - 2009

Y1 - 2009

N2 - Asialoglycoprotein receptor (ASGPR)-mediated endocytosis has been used to target genes to hepatocytes in vivo. However, the level and duration of transgene expression have been low because of lysosomal translocation and degradation of the DNA and lack of its integration into the host genome. In this study we packaged the DNA of interest in proteoliposomes containing the fusogenic galactose-terminated F-glycoprotein of the Sendai virus (FPL) for targeted delivery to hepatocytes. After the FPL binds to ASGPR on the hepatocyte surface, fusogenic activity of the F-protein delivers the DNA into the cytosol, bypassing the endosomal pathway. For transgene integration we designed plasmids containing one transcription unit expressing the Sleeping Beauty transposase (SB) and another expressing human uridinediphosphoglucuronate glucuronosyltransferase-1A1 (pSB-hUGT1A1). The latter was flanked by inverted/direct repeats that are substrates of SB. In cell culture, FPL-mediated delivery of the E. coli β-galactosidase gene (LacZ) resulted in transduction of ASGPR-positive cells (rat hepatocytes or Hepa1 cell line), but not of ASGPR-negative 293 cells. Intravenous injection of the FPL-entrapped pSB-hUGT1A1 (4-8 μg/day, 1-4 doses) into UGT1A1-deficient hyperbilirubinemic Gunn rats (model of Crigler-Najjar syndrome type 1) resulted in hUGT1A1 expression in 5%-10% of hepatocytes, but not in other cell types. Serum bilirubin levels declined by 30% ± 4% in 2 weeks and remained at that level throughout the 7-month study duration. With histidine containing FPL, serum bilirubin was reduced by 40% ± 5%, and bilirubin glucuronides were excreted into bile. No antibodies were detectable in the recipient rats against the F-protein or human UGT1A1. Conclusion: FPL is an efficient hepatocyte-targeted gene delivery platform in vivo that warrants further exploration toward clinical application.

AB - Asialoglycoprotein receptor (ASGPR)-mediated endocytosis has been used to target genes to hepatocytes in vivo. However, the level and duration of transgene expression have been low because of lysosomal translocation and degradation of the DNA and lack of its integration into the host genome. In this study we packaged the DNA of interest in proteoliposomes containing the fusogenic galactose-terminated F-glycoprotein of the Sendai virus (FPL) for targeted delivery to hepatocytes. After the FPL binds to ASGPR on the hepatocyte surface, fusogenic activity of the F-protein delivers the DNA into the cytosol, bypassing the endosomal pathway. For transgene integration we designed plasmids containing one transcription unit expressing the Sleeping Beauty transposase (SB) and another expressing human uridinediphosphoglucuronate glucuronosyltransferase-1A1 (pSB-hUGT1A1). The latter was flanked by inverted/direct repeats that are substrates of SB. In cell culture, FPL-mediated delivery of the E. coli β-galactosidase gene (LacZ) resulted in transduction of ASGPR-positive cells (rat hepatocytes or Hepa1 cell line), but not of ASGPR-negative 293 cells. Intravenous injection of the FPL-entrapped pSB-hUGT1A1 (4-8 μg/day, 1-4 doses) into UGT1A1-deficient hyperbilirubinemic Gunn rats (model of Crigler-Najjar syndrome type 1) resulted in hUGT1A1 expression in 5%-10% of hepatocytes, but not in other cell types. Serum bilirubin levels declined by 30% ± 4% in 2 weeks and remained at that level throughout the 7-month study duration. With histidine containing FPL, serum bilirubin was reduced by 40% ± 5%, and bilirubin glucuronides were excreted into bile. No antibodies were detectable in the recipient rats against the F-protein or human UGT1A1. Conclusion: FPL is an efficient hepatocyte-targeted gene delivery platform in vivo that warrants further exploration toward clinical application.

UR - http://www.scopus.com/inward/record.url?scp=70349241724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349241724&partnerID=8YFLogxK

U2 - 10.1002/hep.23060

DO - 10.1002/hep.23060

M3 - Article

VL - 50

SP - 815

EP - 824

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -